Latest news with #LalPathlabs
Mint
06-08-2025
- Business
- Mint
Coal India, Ramco Cements among 5 key stocks to trade ex-dividend today, 6 August 2025
Dividend stocks 2025: Coal India, The Ramco Cements, Dr. Lal PathLabs, Blue Dart Express Ltd, and The Bombay Dyeing and Manufacturing Company Limited are among the five key stocks to trade ex-dividend today, 6 August 2025. These firms, like many others, have designated August 6, 2025, as the record date for the identification and approval of a list of eligible shareholders for dividends. To be included on the list of eligible shareholders for dividends under the T+1 settlement method, investors should have purchased stock in these companies at least one day before the record date. Coal India Ltd - The Board of Directors at its meeting held on 31 July 2025 had declared the 1st Interim Dividend for the Financial Year 2025-26, which stood at ₹ 5.50/- per equity share on the face value of ₹ 10/-. The company had fixed Wednesday, 6th August 2025, as the 'Record Date' The Ramco Cements Ltd- The Board of Directors had recommended a dividend of ₹ 2/- per share of ₹ l/- each for the year ended 31st March 2025. The dividend on declaration at the ensuing Annual General Meeting will be paid within 30 days thereof. Dr. Lal PathLabs Ltd- Dr Lal Pathlabs had declared an Interim Dividend of ₹ 6/- per equity share (@ 60% on a face value of ₹ 10/-each) for the 2025–2026 fiscal year. The record date for the purpose of payment of the Interim Dividend was set at August 06, 2025 Blue Dart Express Ltd- The company had recommended the payment of a Dividend of ₹ 25/- (Rupees Twenty Five only) per share on the Equity Share for the financial year ended March 31, 2025, subject to necessary approval by the Members at the ensuing Annual. The Bombay Dyeing and Manufacturing Company Limited- The company had recommended the final dividend for the Financial Year ended 31st March, 2025 @60% i.e. ₹ 1.20/- (Rupees One and Twenty Paise Only) per equity share of ₹ 2/- each to be declared at the 145th Annual General Meeting of the Company.
Mint
06-08-2025
- Business
- Mint
Coal India, Ramco Cements among 5 key stocks to trade ex-dividend today, 6 August'2025
Dividend stocks 2025: Coal India, The Ramco Cements , Dr. Lal PathLabs , Blue Dart Express Ltd, and The Bombay Dyeing and Manufacturing Company Limited among 5 key stocks to trade ex-dividend today, 6 August'2025. These firms, like many others, have designated August 6, 2025, as the record date for the identification and approval of a list of eligible shareholders for dividends. To be included on the list of eligible shareholders for dividends under the T+1 settlement method, investors must purchase stock in these companies at least one day before the record date. Coal India Ltd - The Board of Directors at its meeting held on 31 July 2025 had declared 1st Interim Dividend for the Financial Year 2025-26 which stood at ₹ 5.50/- per equity share on the face value of ₹ 10/- as recommended by the Audit CIL Committee during its meeting on this date. The company had fixed Wednesday, 6th August' 2025 as the 'Record Date' The Ramco Cements Ltd- The Board of Directors had recommended a dividend of Rs.2/- per share of ₹ .l/- each for the year ended 31st March 2025. The dividend on declaration at the ensuing Annual General Meeting, will be paid within 30 days thereof. Dr. Lal PathLabs Ltd- Dr Lal Pathlabs had Declared Interim Dividend of ₹ 6/- per equity share (@ 60% on a face value of ₹ 10/-each) for the 2025–2026 fiscal year. The record date for the purpose of payment of Interim Dividend was set at August 06, 2025 Blue Dart Express Ltd- The company had recommended the payment of Dividend of Rs. 25/- (Rupees Twenty Five only) per share on the Equity Share Capital for the financial year ended March 31, 2025, subject to necessary approval by the Members at the ensuing Annual. The Bombay Dyeing and Manufacturing Company Limited- the company had recommended the final dividend for the Financial Year ended 31st March, 2025 @60% i.e. ₹ 1.20/- (Rupees One and Twenty Paise Only) per equity share of ₹ 2/- each to be declared at the 145th Annual General Meeting of the Company. Disclaimer: The views and recommendations above are those of individual analysts or brokerage companies, not Mint. We advise investors to check with certified experts before making any investment decisions.
Mint
24-07-2025
- Business
- Mint
Dr Lal Pathlabs declares board meeting date to announce Q1 results 2025, dividend
Healthcare service provider Dr Lal Pathlabs announced, on Thursday, that board will meet on July 31 to announce the financial results for the quarter ending on June 30, 2025. Dr Lal Pathlabs share price was trading 2.58 per cent up at ₹ 3,095 apiece on Thursday. The stock opened at ₹ 3,017.20 in early morning session, as compared to previous close of ₹ 3,017.20. The healthcare stock has ascended over 13 per cent in a month and nearly 9 per cent in six months. The company also informed the exchanges that the board will also consider recommending interim dividend if any along with the first quarter results. ' This is to inform you that a meeting of the Board of Directors is scheduled to be held on Thursday, July 31, 2025 to inter-alia consider and approve the Un-audited (Standalone & Consolidated) Financial Results of the Company for the Quarter ended June 30, 2025 and to consider recommending Interim Dividend, if any, on the Equity Shares of the Company for the Financial Year 2025-26,' the company said in an exchange filing dated July 24. It also said that the trading window for the securities of the company is closed and shall re-open after 48 hours from the declaration of the aforesaid Financial Results. ' In continuation to our letter dated June 26, 2025 and in line with the provisions of the SEBI (Prohibition of Insider Trading) Regulations, 2015 and Company's code for Prevention of Insider Trading, the Trading Window for dealing in Securities of the Company is closed and shall re-open after 48 hours from the declaration of the aforesaid Financial Results,' it added. Disclaimer: This story is for educational purposes only. The views and recommendations above are those of individual analysts or broking companies, not Mint. We advise investors to check with certified experts before making any investment decisions.
Business Standard
25-06-2025
- Business
- Business Standard
Dr Lal Pathlabs strengthens its genomics capabilities with Illumina's NovaSeq X Series
Dr Lal Pathlabs (DLPL) has expanded its genomics capabilities by adding Illumina's NovaSeq X Series to its dedicated genomics division, Genevolve. With the integration of Illumina's latest technology, DLPL can now deliver faster and more accurate genomic research insights. The NovaSeq X system features Illumina's cutting-edge XLEAP-SBS chemistry, offering unmatched throughput, accuracy, and sustainability. The NovaSeq X Plus can generate more than 20,000 whole genomes per year, more than double the throughput of Illumina's previous sequencers. Its unprecedented speed, scale, and accuracy push the limits of what's possible in genetic sequencing. And its powerful technology allows users to unlock previously unimaginable discoveries and advancements. With the addition of Illumina's NovaSeq X Series, we are taking another step forward in driving innovation and scientific excellence, said Mr. Shankha Banerjee, CEO, Dr. Lal PathLabs Limited. This investment allows us to broaden our capabilities and contribute meaningfully to India's evolving genomics landscape. Launched in 2019, Genevolve has swiftly emerged as a DNA-based center of excellence. The addition of Illumina products further strengthens Genevolve's position as a pioneer in next-generation sequencing (NGS), enabling DLPL to deliver actionable, AI-powered insights with greater speed and sensitivity.
Time of India
21-06-2025
- Health
- Time of India
Delhi consumer panel upholds verdict indicting Dr Lal Pathlabs for wrong report
New Delhi: The Delhi State Consumer Disputes Redressal Commission has upheld a finding on Dr Lal Pathlabs being deficient in service and ordering it pay compensation to a patient over a wrong lab report . The state consumer commission's president Sangita Dhingra Sehgal and judicial member Pinki were hearing the lab's appeal against the August 2014 order of a district forum indicting the lab for a wrong test report and ordering Rs 3.5 lakh compensation. In its order on May 26, the commission said, "When a patient's urea levels are reported at more than ten times the normal range, triggering emergency hospitalisation and profound distress, the laboratory cannot retreat behind semantic arguments about its limited role in the diagnostic chain. Moreover, the appellant's (Lal Pathlabs) attempt to shift blame onto prescribing physicians or the Respondent's medical history holds no ground." It said if the tests carried out by a laboratory are defective and erroneous, the diagnosis by a doctor will be incorrect, resulting in improper treatment and the "medicines prescribed based on a wrong test report and diagnosis may lead to fatal results for the patient". "When multiple test reports from different laboratories show consistent results that differ significantly from one laboratory's findings, it creates a strong presumption of deficiency in service by the outlier laboratory," the commission added. Rejecting the lab's argument that the results were due to a particular drug consumed by the complainant, the commission said, "Even if it is assumed that the respondent (complainant) was taking Spirex tablets, we find it implausible that there could be such astronomical difference in patient's test reports pertaining to creatine and urea." It also rejected the lab's argument that the complainant did not agree to their request for re-collecting the sample, saying the report depicted the values of various important health indicators to be so high that any person having ordinary prudence would be perturbed by such results. "The respondent was under no obligation to get the tests redone. He got another test done from 3 labs, viz. Max Health Care, Dr Dangs Laboratory and Super Religare Laboratories Ltd, all of which depicted his parameters to be within the normal range," the commission said. The medical expenses incurred by the patient, in the panel's opinion, were directly attributable to the lab's erroneous report, which falsely indicated life-threatening conditions and necessitated emergency hospitalisation. The commission noted the discharge summary from Max Hospital "explicitly" linking the patient's admission there to the "erroneous outside lab report". "Being misdiagnosed with life-threatening conditions and undergoing unnecessary hospitalisation constitutes severe psychological trauma. The mental agony and physical suffering cannot be understated." The panel found the direction for compensation "just and reasonable". "We concur with the district commission's finding that the appellant failed to maintain the standard of reasonable care expected in pathological testing, thus amounting to a deficiency in service," it held.
